ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Neuropharmacology
Health Risks of Cocaine Adulteration: Local Anesthetics as Modulators of Monoamine and Organic Cation Transporters
Provisionally accepted- Medical University of Vienna, Vienna, Austria
 
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Local anesthetics (LAs) are frequently used as adulterants in cocaine sold on the illicit market, sometimes in higher quantities than cocaine itself. These agents can mimic cocaine's anesthetic effect, masking the products reduced purity. While reports suggest that LAs influence monoaminergic neurotransmission, systematic evidence remains limited. We examined three LAs commonly detected in cocaine samples submitted for drug checking from Vienna, Austria—procaine, benzocaine, and lidocaine—for their activity on uptake-1 monoamine transporters (DAT, NET, SERT) and uptake-2 organic cation transporters (OCT1–3). Transporter activity was measured in vitro, and computational docking was applied to explore molecular interactions with atomistic detail. Procaine and benzocaine inhibited DAT and NET at physiologically relevant concentrations, whereas neither compound affected SERT. Procaine also inhibited OCT1 and OCT2 with affinities comparable to or greater than cocaine, while benzocaine exhibited no OCT activity. Lidocaine had no significant effect on any transporter. Docking studies confirmed procaine binding within the DAT substrate pocket, consistent with its inhibitory profile. Although LAs modulate uptake-1 and uptake-2 transporters, their actions are insufficient to replicate cocaine's psychoactive effects. However, their impact on OCTs indicates potential health risks, highlighting the importance of accessible drug checking services for harm reduction.
Keywords: Local anesthetics, Cocaine adulteration, monoamine transporters, OCT inhibition, Harm Reduction
Received: 04 Sep 2025; Accepted: 03 Nov 2025.
Copyright: © 2025 Kudlacek, Senning, Karden, Ludwig, Bicher, Kooti, Holy, Stockner, Luf and Sitte. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Harald  H Sitte, harald.sitte@meduniwien.ac.at
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
